Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to Reduce Airway Glucose in COPD Patients
NCT03651895Phase 2Completed
- Sponsor
- Imperial College London
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metformin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Imperial College London. Primary endpoint: Sputum Glucose Concentration at 3 months. Started May 2022; status: completed.
02
Drugs
metformin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03651895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651895.